Everything you need to know about the record CSL dividend

CSL's latest dividend is its biggest yet…

| More on:
Man holding out Australian dollar notes, symbolising dividends.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a bouncy but positive day for the S&P/ASX 200 Index (ASX: XJO) and many ASX 200 shares this Tuesday. After starting the week off on a strong footing yesterday, the ASX 200 is continuing that momentum today, with the index currently up 0.05%. But let's talk about what's happening with CSL Ltd (ASX: CSL) shares.

CSL shares are not faring as well as the broader market, to put it nicely. In fact, the ASX 200 healthcare giant is having an awful day.

Yesterday, the CSL share price closed at $308.93. But this morning, those same shares opened at just $300.03 and are currently trading at $296.37. That's down a hefty 4.07% for the day thus far.

It seems investors are not too impressed with the full-year earnings report that the company dropped this morning.

As we covered at the time, these earnings contained some fairly impressive figures. CSL reported an 11% bump in revenues for the 12 months to 30 June to US$14.8 billion.

That helped push the company's net profit after tax before amortisation (NPATA) up by 11% to US$2.91 billion, or up 15% to US$3.01 billion in constant currency terms.

As my Fool colleague covered after market open, it seems that investors may have been disappointed by CSL's guidance for FY2025. The company is expecting to record revenue growth of between 5-7% for the 12 months to 30 June 2025, and an NPATA of between US$3.2 and US$3.3 billion.

But let's talk about the supersized dividend that CSL has just revealed.

CSL ups its dividend to new record high

This morning, CSL revealed that its final dividend for FY2024 would come in at US$1.45 per share. That's a healthy 12.4% rise over the final dividend of US$1.29 ($2.01) per share that investors received last year, as well as a 21.85% increase over April's interim dividend of US$1.19 ($1.80) per share.

We don't yet know whether this latest payment will be in Australian dollars, but at today's exchange rates, US$1.45 would equate to approximately $2.20 per share. Like April's interim dividend, it will not come with any franking credits attached.

Nevertheless, this is a big deal for CSL, as this latest dividend represents a record-high shareholder payout for the company.

However, shareholders will have to wait a while until this passive income arrives in their bank accounts. CSL has scheduled Monday, 9 September next month as this payment's ex-dividend date. So anyone wishing to bag this payout will have to own CSL shares by market close on Friday, 6 September.

The payment date will then roll around on 2 October.

CSL's dividend reinvestment plan (DRP) is not operating for this payment, so shareholders have no other option than to receive a traditional cash payment.

At today's pricing, CSL shares have a trailing dividend yield of 1.28%. If we factor in the newly announced dividend, CSL would have a forward dividend yield of 1.35%.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Key Canadian approval sends 10-bagger biotech's shares higher

This 10-bagger company has just released more good news, with a breakthrough in the Canadian market.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This biotech has lodged a key submission with US regulators

This company has lodged a key submission which will pave the way for sales of its heart failure software in…

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Let’s look at what experts are expecting from the healthcare giant in 2026.

Read more »

medical doctor performing surgery using surgical instruments
Healthcare Shares

Biotech company implants heart device in world first

This biotech company has implanted a heart device as part of a clinical trial looking to open up new markets.

Read more »